These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23522741)

  • 1. Current options for the treatment of facial angiofibromas.
    Salido-Vallejo R; Garnacho-Saucedo G; Moreno-Giménez JC
    Actas Dermosifiliogr; 2014; 105(6):558-68. PubMed ID: 23522741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted topical and combination laser surgery for the treatment of angiofibromas.
    Bae-Harboe YS; Geronemus RG
    Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facial angiofibromas treated by rapamycin 0.05% ointment and a combined laser therapy.
    Negosanti F; Tengattini V; Gurioli C; Neri I
    J Cosmet Dermatol; 2018 Oct; 17(5):762-765. PubMed ID: 30123982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy.
    Park J; Yun SK; Cho YS; Song KH; Kim HU
    Dermatology; 2014; 228(1):37-41. PubMed ID: 24401865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
    Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
    Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
    Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P
    Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
    Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of angiofibromas of tuberous sclerosis with 5-aminolevulinic acid blue light photodynamic therapy followed by immediate pulsed dye laser.
    Weinberger CH; Endrizzi B; Hook KP; Lee PK
    Dermatol Surg; 2009 Nov; 35(11):1849-51. PubMed ID: 19682000
    [No Abstract]   [Full Text] [Related]  

  • 9. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
    Foster RS; Bint LJ; Halbert AR
    Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
    Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
    JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
    Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
    JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
    Dill PE; De Bernardis G; Weber P; Lösch U
    Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
    Wheless JW; Almoazen H
    J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
    Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
    Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
    Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
    Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.
    Salido R; Garnacho-Saucedo G; Cuevas-Asencio I; Ruano J; Galán-Gutierrez M; Vélez A; Moreno-Giménez JC
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1315-8. PubMed ID: 21834948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unilateral facial angiofibromas without other evidence of tuberous sclerosis: case report and review of the literature.
    Hall MR; Kovach BT; Miller JL
    Cutis; 2007 Oct; 80(4):284-8. PubMed ID: 18038689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence.
    Cortell Fuster C; Martínez Gómez MA; Cercós Lleti AC; Climente Martí M
    J Dermatolog Treat; 2022 Jun; 33(4):1804-1810. PubMed ID: 33821748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis.
    Weiss ET; Geronemus RG
    Lasers Surg Med; 2010 Jul; 42(5):357-60. PubMed ID: 20583249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Angiofibromas in a Tuberous Sclerosis Patient Using Topical Timolol 0.5% Gel.
    Krakowski AC; Nguyen TA
    Pediatrics; 2015 Sep; 136(3):e709-13. PubMed ID: 26304829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.